Close Menu

NEW YORK – M2Gen said Wednesday that it has received an unspecified new investment from Clayton, Dubilier & Rice, the Merck Global Health Innovation Fund, and McKesson Ventures. M2Gen said that the investment makes private equity firm CD&R its largest shareholder.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.